Dr. Jingdong Su
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 976
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license Q8359 (first issued 2016; active) -
Internal Medicine Physician
TX license Q8359 (first issued 2016; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Mother Frances Hospital Tyler, TX
- Christus Mother Frances Hospital Sulphur Springs Sulphur Springs, TX
- Christus Mother Frances Hospital- Jacksonville Jacksonville, TX
- Ut Health East Texas Quitman Hospital Quitman, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 976
- Services billed
- 146,625
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 24,480 | 35 |
| Injection, oxaliplatin, 0.5 mg | 13,900 | 29 |
| Injection, nivolumab, 1 mg | 13,880 | 20 |
| Injection, pembrolizumab, 1 mg | 12,800 | 32 |
| Injection, paclitaxel, 1 mg | 11,094 | 38 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 8,935 | 22 |
| Injection, iron sucrose, 1 mg | 7,000 | 24 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,760 | 70 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,940 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,451 | 174 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Tyler, TX | 355 |
| Alendronate Sodium Other prescribers in Tyler, TX | 141 |
| Gabapentin Other prescribers in Tyler, TX | 69 |
| Hydroxyurea Other prescribers in Tyler, TX | 69 |
| Revlimid (lenalidomide) | 69 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Tyler, TX | 64 |
| Acyclovir Other prescribers in Tyler, TX | 61 |
| Dexamethasone Other prescribers in Tyler, TX | 54 |
| Anastrozole Other prescribers in Tyler, TX | 44 |
| Levothyroxine Sodium Other prescribers in Tyler, TX | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 35 companies reported 100 payments worth $3,151 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $305 |
|---|---|
| Tempus Ai, Inc | $304 |
| AbbVie Inc. | $272 |
| Regeneron Healthcare Solutions, Inc. | $160 |
| Janssen Biotech, Inc. | $160 |
| Incyte Corporation | $150 |
| Genzyme Corporation | $146 |
| Pharmaessentia USA Corporation | $146 |
| Food and Beverage | $3,058 |
|---|---|
| Education | $92.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Sep 23, 2025 | Education IMBRUVICA · ONCOLOGY · in-kind | $92.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.